For example, patients who are older than 55 and have DM might be better served by treatment with a leukocyte trafficking inhibitor such as vedolizumab rather than an anti-tumor necrosis factor agent (anti-TNF), which have been associated with higher risk of serious infections [19]. This evidence concerns the gene TNF and diabetes mellitus.